Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
The development of immune checkpoint inhibitors has revolutionized the landscape of treatment of advanced melanoma in recent years. Based on the efficacy results of the phase III CheckMate 067 trial, nivolumab in combination with ipilimumab is one of the first-line standard options for advanced mela...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1187840/full |
| _version_ | 1797800901859082240 |
|---|---|
| author | Lucía Vázquez-Montero María del Carmen Álamo de la Gala Luis de la Cruz-Merino Luis de la Cruz-Merino Luis de la Cruz-Merino |
| author_facet | Lucía Vázquez-Montero María del Carmen Álamo de la Gala Luis de la Cruz-Merino Luis de la Cruz-Merino Luis de la Cruz-Merino |
| author_sort | Lucía Vázquez-Montero |
| collection | DOAJ |
| description | The development of immune checkpoint inhibitors has revolutionized the landscape of treatment of advanced melanoma in recent years. Based on the efficacy results of the phase III CheckMate 067 trial, nivolumab in combination with ipilimumab is one of the first-line standard options for advanced melanoma along with pembrolizumab, nivolumab, and, recently, nivolumab plus relatlimab. Counterbalancing its efficacy, nivolumab plus ipilimumab is associated with severe immune-related toxicity. This article will review the efficacy and safety of the nivolumab plus ipilimumab combination in advanced melanoma across phase I, II, and III clinical trials that evaluated this approach. We also explore the benefit of the combination schedule across different subgroups of patients and possible predictive biomarkers for efficacy outcomes in order to elucidate which patients could be the best candidates for combination or single-agent therapy. Patients with BRAF-mutant tumours, asymptomatic brain metastases, or PD-L1-negative status appear to reach better survival outcomes with the combination relative to single-agent immunotherapy. |
| first_indexed | 2024-03-13T04:42:14Z |
| format | Article |
| id | doaj.art-420f01958705471bbfd0c7f1fc9d8bd7 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-13T04:42:14Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-420f01958705471bbfd0c7f1fc9d8bd72023-06-19T05:09:23ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-06-011310.3389/fonc.2023.11878401187840Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulationsLucía Vázquez-Montero0María del Carmen Álamo de la Gala1Luis de la Cruz-Merino2Luis de la Cruz-Merino3Luis de la Cruz-Merino4Clinical Oncology Department, University Hospital Virgen Macarena, Seville, SpainClinical Oncology Department, University Hospital Virgen Macarena, Seville, SpainClinical Oncology Department, University Hospital Virgen Macarena, Seville, SpainSchool of Medicine. University of Seville, Seville, SpainCancer Immunotherapy, Department of Oncohematology and Genetics, Biomedicine Institute of Seville (IBIS)/CSIC Spanish National Research Council, Seville, SpainThe development of immune checkpoint inhibitors has revolutionized the landscape of treatment of advanced melanoma in recent years. Based on the efficacy results of the phase III CheckMate 067 trial, nivolumab in combination with ipilimumab is one of the first-line standard options for advanced melanoma along with pembrolizumab, nivolumab, and, recently, nivolumab plus relatlimab. Counterbalancing its efficacy, nivolumab plus ipilimumab is associated with severe immune-related toxicity. This article will review the efficacy and safety of the nivolumab plus ipilimumab combination in advanced melanoma across phase I, II, and III clinical trials that evaluated this approach. We also explore the benefit of the combination schedule across different subgroups of patients and possible predictive biomarkers for efficacy outcomes in order to elucidate which patients could be the best candidates for combination or single-agent therapy. Patients with BRAF-mutant tumours, asymptomatic brain metastases, or PD-L1-negative status appear to reach better survival outcomes with the combination relative to single-agent immunotherapy.https://www.frontiersin.org/articles/10.3389/fonc.2023.1187840/fullnivolumabipilimumabadvanced melanomasafetyefficacy |
| spellingShingle | Lucía Vázquez-Montero María del Carmen Álamo de la Gala Luis de la Cruz-Merino Luis de la Cruz-Merino Luis de la Cruz-Merino Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations Frontiers in Oncology nivolumab ipilimumab advanced melanoma safety efficacy |
| title | Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations |
| title_full | Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations |
| title_fullStr | Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations |
| title_full_unstemmed | Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations |
| title_short | Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations |
| title_sort | nivolumab plus ipilimumab in metastatic melanoma a critical appraisal focused on specific subpopulations |
| topic | nivolumab ipilimumab advanced melanoma safety efficacy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1187840/full |
| work_keys_str_mv | AT luciavazquezmontero nivolumabplusipilimumabinmetastaticmelanomaacriticalappraisalfocusedonspecificsubpopulations AT mariadelcarmenalamodelagala nivolumabplusipilimumabinmetastaticmelanomaacriticalappraisalfocusedonspecificsubpopulations AT luisdelacruzmerino nivolumabplusipilimumabinmetastaticmelanomaacriticalappraisalfocusedonspecificsubpopulations AT luisdelacruzmerino nivolumabplusipilimumabinmetastaticmelanomaacriticalappraisalfocusedonspecificsubpopulations AT luisdelacruzmerino nivolumabplusipilimumabinmetastaticmelanomaacriticalappraisalfocusedonspecificsubpopulations |